BUSINESS COMBINATIONS (Details) shares in Thousands, $ in Thousands				3 Months Ended		9 Months Ended
	May 03, 2021 USD ($) shares	Apr. 30, 2021 USD ($)	Nov. 29, 2019 USD ($) shares	Jun. 30, 2021 USD ($) segment	Jun. 30, 2020 USD ($)	Jun. 30, 2021 USD ($) segment	Jun. 30, 2020 USD ($)
BUSINESS COMBINATIONS
Consideration in cash						$ 40,698	$ 4,000
Revenues				$ 22,892	$ 15,765	59,529	44,695
Net loss				(2,265)	$ (879)	(3,354)	$ (2,893)
Pre-Clinical Research Services, Inc.
BUSINESS COMBINATIONS
Contingent consideration			$ 2,500
Shares issued | shares			240
Common shares value			$ 1,133
Principal amount			$ 800
Intangible assets				2,081		2,081
Cash and equivalents assumed				1,500		1,500
Tangible and identifiable intangible assets				5,857		5,857
Effective percentage rate			4.50%
Revenues						5,191
Net loss						117
HistoTox Labs
BUSINESS COMBINATIONS
Consideration in cash		$ 22,321
Intangible assets				8,500		8,500
Tangible and identifiable intangible assets				22,321		22,321
Transaction costs				449		$ 560
Acquisition term						1 year
Goodwill impairment losses						$ 0
Bolder BioPATH
BUSINESS COMBINATIONS
Shares issued | shares	1,588
Common shares value	$ 34,452
Principal amount	1,500
Escrow Deposit Disbursements Related to Property Acquisition	1,250
Intangible assets				12,500		12,500
Cash and equivalents assumed	$ 18,500			124		124
Tangible and identifiable intangible assets				54,452		54,452
Transaction costs				$ 450		$ 568
Acquisition term						1 year
Goodwill impairment losses						$ 0
HistoTox Labs and Bolder BioPATH combined
BUSINESS COMBINATIONS
Number of Operating Segments | segment				1		1
Revenues				$ 4,251		$ 4,251
Net loss				$ 585		$ 585
Customer Relationships | HistoTox Labs
BUSINESS COMBINATIONS
Weighted-average estimated useful life						8 years
Customer Relationships | Bolder BioPATH
BUSINESS COMBINATIONS
Weighted-average estimated useful life						8 years
Noncompete Agreements | HistoTox Labs
BUSINESS COMBINATIONS
Weighted-average estimated useful life						5 years